

Leonard B Saltz

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1606570/leonard-b-saltz-publications-by-year.pdf>

Version: 2024-04-05

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

421 papers	43,748 citations	111 h-index	203 g-index
459 ext. papers	51,424 ext. citations	6.4 avg, IF	6.94 L-index

#	Paper	IF	Citations
421	Diet- and Lifestyle-Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance).. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101784	2.2	3
420	Efficacy of bevacizumab-based treatment in early-onset treatment-naïve metastatic colorectal cancer patients: An ARCAD database analysis.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 101-101	2.2	
419	Associations Between Unprocessed Red Meat and Processed Meat With Risk of Recurrence and Mortality in Patients With Stage III Colon Cancer.. <i>JAMA Network Open</i> , 2022 , 5, e220145	10.4	1
418	Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2200032	2.2	14
417	The Hardest Weeks of My Life: A Qualitative Study of Experiences, Practice Changes, and Emotional Burden of New York City Oncology Physicians During the COVID-19 Surge in 2020.. <i>JCO Oncology Practice</i> , 2021 , OP2100585	2.3	1
416	Development and Assessment of a Clinical Calculator for Estimating the Likelihood of Recurrence and Survival Among Patients With Locally Advanced Rectal Cancer Treated With Chemotherapy, Radiotherapy, and Surgery. <i>JAMA Network Open</i> , 2021 , 4, e2133457	10.4	2
415	Recommendations for Testing and Treating Outpatient Cancer Patients in the Era of COVID-19. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 820-822	9.7	5
414	Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments. <i>Journal of Clinical Oncology</i> , 2021 , 39, 950-955	2.2	11
413	Clinical Calculator Based on Molecular and Clinicopathologic Characteristics Predicts Recurrence Following Resection of Stage I-III Colon Cancer. <i>Journal of Clinical Oncology</i> , 2021 , 39, 911-919	2.2	9
412	Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021 , 19, 329-359	7.3	153
411	In Defense of TNT: A Dynamite Strategy. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1185-1186	2.2	1
410	Race, Income, and Survival in Stage III Colon Cancer: CALGB 89803 (Alliance). <i>JNCI Cancer Spectrum</i> , 2021 , 5, pkab034	4.6	1
409	The rate and risk of secondary pelvic malignancies (SPM) in patients treated with definitive radiation for locally advanced rectal cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 12065-12065	2.2	
408	Clinicopathological and molecular characteristics of early-onset stage III colon adenocarcinoma: An analysis of 25 studies with 35,713 patients in the Adjuvant Colon Cancer End Points (ACCENT) database.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3597-3597	2.2	
407	Randomized blinded study comparing injection site pain from octreotide long-acting-release (LAR) versus lanreotide during the treatment of well differentiated neuroendocrine tumors (WDNETs).. <i>Journal of Clinical Oncology</i> , 2021 , 39, e16204-e16204	2.2	
406	Adverse event load, onset, and maximum grade: A novel method of reporting adverse events in cancer clinical trials. <i>Clinical Trials</i> , 2021 , 18, 51-60	2.2	1
405	Characterization and Clinical Outcomes of DNA Mismatch Repair-deficient Small Bowel Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021 , 27, 1429-1437	12.9	9

404	The Landmark Series: Chemotherapy for Non-Metastatic Colon Cancer. <i>Annals of Surgical Oncology</i> , 2021 , 28, 995-1001	3.1	1
403	Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 400-407	9.7	12
402	Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair-proficient Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 2200-2208	12.9	7
401	Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211020547	5.4	2
400	A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers. <i>Journal of the National Cancer Institute</i> , 2021 ,	9.7	12
399	Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database. <i>Journal of the National Cancer Institute</i> , 2021 ,	9.7	3
398	Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19. <i>JAMA Oncology</i> , 2020 , 6, 1694-1695	13.4	13
397	The Diet of Higher Insulinemic Potential Is Not Associated with Worse Survival in Patients with Stage III Colon Cancer (Alliance). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 1692-1695	4	2
396	Mismatch Repair-Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy. <i>Clinical Cancer Research</i> , 2020 , 26, 3271-3279	12.9	41
395	L1CAM defines the regenerative origin of metastasis-initiating cells in colorectal cancer. <i>Nature Cancer</i> , 2020 , 1, 28-45	15.4	59
394	Coaltered and Is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 1077-1085	12.9	37
393	Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative. <i>European Journal of Cancer</i> , 2020 , 130, 63-71	7.5	7
392	Preliminary results of the organ preservation of rectal adenocarcinoma (OPRA) trial.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4008-4008	2.2	98
391	Sex differences in efficacy and toxicity of first-line treatment of metastatic colorectal cancer (CRC): An analysis of 18,399 patients in the ARCAD database.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4029-4029 ^{2.2}	2.2	4
390	A phase II study of induction PD-1 blockade in subjects with locally advanced mismatch repair-deficient rectal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS4123-TPS4123	2.2	1
389	NCCN Guidelines Insights: Rectal Cancer, Version 6.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 806-815	7.3	105
388	Actionable alterations (AA) in gastrointestinal (GI) cancers: Rate of detection and receipt of matched therapies (MT).. <i>Journal of Clinical Oncology</i> , 2020 , 38, e15677-e15677	2.2	
387	Immediate post-thermal ablation biopsy of colorectal liver metastases to predict oncologic outcomes.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4602-4602	2.2	

386	Clinicopathological and molecular biological characteristics of early-onset stage II/III colorectal adenocarcinoma: An analysis of 25 studies with 47,184 patients (pts) in the adjuvant colon cancer end points (ACCENT) database.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4099-4099	2.2	1
385	Survival outcomes among older adults (OA) receiving second-line therapy for metastatic CRC (mCRC): 5,289 patients (pts) from the ARCAD Clinical Trials Program.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 7009-7009	2.2	
384	Understanding the Right to Try Act. <i>Clinical Cancer Research</i> , 2020 , 26, 340-343	12.9	3
383	Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, 60-67	13.4	55
382	Lack of Availability and Efficacy of Phase I and Basket Trials for Patients With Gastrointestinal Cancers. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 438-442	9.7	
381	Reply to S. Boutayeb et al. <i>JCO Oncology Practice</i> , 2020 , 16, 525	2.3	1
380	Outcomes of ICU Admission of Patients With Progressive Metastatic Gastrointestinal Cancer. <i>Journal of Intensive Care Medicine</i> , 2020 , 35, 297-302	3.3	4
379	Management of Locally Advanced Rectal Cancer During The COVID-19 Pandemic: A Necessary Paradigm Change at Memorial Sloan Kettering Cancer Center. <i>Advances in Radiation Oncology</i> , 2020 , 5, 687-689	3.3	21
378	Phase I Study of Trifluridine/Tipiracil Plus Irinotecan and Bevacizumab in Advanced Gastrointestinal Tumors. <i>Clinical Cancer Research</i> , 2020 , 26, 1555-1562	12.9	4
377	Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2019 , 2, e1911750	10.4	1
376	A rectal cancer organoid platform to study individual responses to chemoradiation. <i>Nature Medicine</i> , 2019 , 25, 1607-1614	50.5	149
375	Molecular and cytogenetic characteristics of myeloid malignancies following luminal gastrointestinal cancer. <i>Leukemia Research</i> , 2019 , 82, 19-23	2.7	
374	Contemporary Validation of a Nomogram Predicting Colon Cancer Recurrence, Revealing All-Stage Improved Outcomes. <i>JNCI Cancer Spectrum</i> , 2019 , 3, pkz015	4.6	11
373	Value-Added Decisions in Oncology. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019 , 39, 122-131	7.1	3
372	Precision oncology giveth and precision oncology taketh away. <i>Lancet Oncology, The</i> , 2019 , 20, 464-466	21.7	2
371	Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial. <i>European Journal of Cancer</i> , 2019 , 111, 82-93	7.5	7
370	Induction Chemotherapy Reduces Patient-reported Toxicities During Neoadjuvant Chemoradiation with Intensity Modulated Radiotherapy for Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2019 , 18, 167-174	3.8	2
369	Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. <i>Journal of Clinical Oncology</i> , 2019 , 37, 286-295	2.2	203

368	Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance). <i>Journal of the National Cancer Institute</i> , 2019 , 111, 170-179	9.7	11
367	Challenges and solutions in the design and execution of the PROSPECT Phase II/III neoadjuvant rectal cancer trial (NCCTG N1048/Alliance). <i>Clinical Trials</i> , 2019 , 16, 165-175	2.2	30
366	Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 1109-1133	7.3	43
365	PCK1 and DHODH drive colorectal cancer liver metastatic colonization and hypoxic growth by promoting nucleotide synthesis. <i>ELife</i> , 2019 , 8,	8.9	26
364	Cellular localization of PD-L1 expression in mismatch-repair-deficient and proficient colorectal carcinomas. <i>Modern Pathology</i> , 2019 , 32, 110-121	9.8	14
363	SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance. <i>Clinical Cancer Research</i> , 2019 , 25, 1948-1956	12.9	48
362	Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy. <i>JAMA Oncology</i> , 2019 , 5, e185896	13.4	180
361	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. <i>Nature Genetics</i> , 2019 , 51, 202-206	36.3	1435
360	Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions. <i>Cancer Research</i> , 2019 , 79, 1047-1053	10.1	73
359	FOLFACIS Treatment and Genomic Correlates of Response in Advanced Anal Squamous Cell Cancer. <i>Clinical Colorectal Cancer</i> , 2019 , 18, e39-e52	3.8	9
358	Pelvic MRI after induction chemotherapy and before long-course chemoradiation therapy for rectal cancer: What are the imaging findings?. <i>European Radiology</i> , 2019 , 29, 1733-1742	8	7
357	NCCN Guidelines Insights: Colon Cancer, Version 2.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018 , 16, 359-369	7.3	433
356	Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis: The CALGB 89803/Alliance Trial. <i>JAMA Oncology</i> , 2018 , 4, 783-790	13.4	71
355	First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2018 , 36, 860-868	4.3	2
354	The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia. <i>Journal of the National Cancer Institute</i> , 2018 , 110, 888-894	9.7	15
353	Marine Ω Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018 , 27, 438-445	4	34
352	Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. <i>Clinical Cancer Research</i> , 2018 , 24, 1326-1336	12.9	198
351	Author@ Response. <i>Journal of Pain and Symptom Management</i> , 2018 , 55, e2-e3	4.8	

350	Association of Preoperative and Postoperative Serum Carcinoembryonic Antigen and Colon Cancer Outcome. <i>JAMA Oncology</i> , 2018 , 4, 309-315	13.4	79
349	Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018 , 16, 50-58	7.3	22
348	Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. <i>Cancer Cell</i> , 2018 , 33, 125-136.e3	24.3	338
347	Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. <i>JAMA Oncology</i> , 2018 , 4, e180071	13.4	205
346	Dietary Fat Intake after Colon Cancer Diagnosis in Relation to Cancer Recurrence and Survival: CALGB 89803 (Alliance). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018 , 27, 1227-1230	4	8
345	Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018 , 16, 852-871	7.3	63
344	Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018 , 16, 874-901	7.3	429
343	Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance). <i>PLoS ONE</i> , 2018 , 13, e0199244	3.7	12
342	NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018 , 16, 693-702	7.3	189
341	The Impact of Primary Tumor Location on Long-Term Survival in Patients Undergoing Hepatic Resection for Metastatic Colon Cancer. <i>Annals of Surgical Oncology</i> , 2018 , 25, 431-438	3.1	53
340	Can We Afford That CAR? Confronting the Effect of Novel Immunotherapies on Future Health Care Costs. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1381-1382	2.2	4
339	Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance). <i>Journal of Clinical Oncology</i> , 2018 , 36, 1112-1120	2.2	32
338	Assessing the Value of Next-Generation Sequencing Tests in a Dynamic Environment. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018 , 38, 139-146	7.1	8
337	Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2018 , 119, 1451-1455	8.7	14
336	Grain Intake and Clinical Outcome in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). <i>JNCI Cancer Spectrum</i> , 2018 , 2, pky017	4.6	5
335	Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention. <i>Clinical Cancer Research</i> , 2018 , 24, 4154-4161	12.9	182
334	Chromosome 20q Amplification Defines a Subtype of Microsatellite Stable, Left-Sided Colon Cancers with Wild-type RAS/RAF and Better Overall Survival. <i>Molecular Cancer Research</i> , 2017 , 15, 708-713	6.6	11
333	Universal screening for microsatellite instability in colorectal cancer in the clinical genomics era: new recommendations, methods, and considerations. <i>Familial Cancer</i> , 2017 , 16, 525-529	3	14

332	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. <i>Nature Medicine</i> , 2017 , 23, 703-713	50.5	1638
331	Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations. <i>Clinical Cancer Research</i> , 2017 , 23, 4753-4760	12.9	47
330	Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma-A New Look at an Old Drug. <i>Oncologist</i> , 2017 , 22, 1102-1106	5.7	24
329	Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma. <i>Oncologist</i> , 2017 , 22, 780-e65	5.7	14
328	Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017 , 15, 370-398	7.3	485
327	Capecitabine With Mitomycin Reduces Acute Hematologic Toxicity and Treatment Delays in Patients Undergoing Definitive Chemoradiation Using Intensity Modulated Radiation Therapy for Anal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 98, 1087-1095	4	31
326	Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. <i>Cancer Research</i> , 2017 , 77, 6513-6523	10.1	43
325	OncoKB: A Precision Oncology Knowledge Base. <i>JCO Precision Oncology</i> , 2017 , 2017,	3.6	699
324	Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1929-1937	2.2	28
323	An elderly man with remote history of metastatic melanoma now with localized pancreas cancer and new liver masses. <i>Journal of Gastrointestinal Oncology</i> , 2017 , 8, 596-602	2.8	
322	FDA Approval of Tisagenlecleucel: Promise and Complexities of a \$475 000 Cancer Drug. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 318, 1861-1862	27.4	102
321	Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 318, 825-835	27.4	235
320	Discharge to Subacute Rehabilitation Facilities Does Not Benefit Patients Hospitalized With Progressive Gastrointestinal Cancer. <i>Journal of Pain and Symptom Management</i> , 2017 , 54, e4-e7	4.8	4
319	Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. <i>Clinical Cancer Research</i> , 2017 , 23, 6094-6100	12.9	107
318	Commentary: Somatostatin analogs-How we choose, and why. <i>Seminars in Oncology</i> , 2017 , 44, 157-158	5.5	1
317	Clinical and genetic determinants of ovarian metastases from colorectal cancer. <i>Cancer</i> , 2017 , 123, 11346-11350	14.3	30
316	A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803. <i>Oncologist</i> , 2017 , 22, 107-114	5.7	10
315	Total neoadjuvant therapy for locally advanced rectal cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 662-662	6.2	3

314	How Should We Intervene on the Financial Toxicity of Cancer Care? One Shot, Four Perspectives. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017 , 37, 35-39	7.1	24
313	MicroRNA-203 predicts human survival after resection of colorectal liver metastasis. <i>Oncotarget</i> , 2017 , 8, 18821-18831	3.3	16
312	Bevacizumab in colorectal cancer: it should have worked. <i>Lancet Oncology, The</i> , 2016 , 17, 1469-1470	21.7	7
311	Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. <i>Lancet Oncology, The</i> , 2016 , 17, 1709-1719	21.7	258
310	Value in Colorectal Cancer Treatment: Where It Is Lacking, and Why. <i>Cancer Journal (Sudbury, Mass)</i> , 2016 , 22, 232-5	2.2	6
309	Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2925-34	2.2	384
308	A Phase II Efficacy and Safety, Open-Label, Multicenter Study of Imprime PGG Injection in Combination With Cetuximab in Patients With Stage IV KRAS-Mutant Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2016 , 15, 222-7	3.8	24
307	Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1182-9	2.2	22
306	Genetic Screening in All Young Patients With Colorectal Cancer?. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1560	2.2	1
305	The Value of Considering Cost, and the Cost of Not Considering Value. <i>Journal of Clinical Oncology</i> , 2016 , 34, 659-60	2.2	21
304	Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF. <i>Molecular Cancer Research</i> , 2016 , 14, 296-301	6.6	34
303	Overspending driven by oversized single dose vials of cancer drugs. <i>BMJ, The</i> , 2016 , 352, i788	5.9	68
302	Multiparametric MRI in the assessment of response of rectal cancer to neoadjuvant chemoradiotherapy: A comparison of morphological, volumetric and functional MRI parameters. <i>European Radiology</i> , 2016 , 26, 4303-4312	8	51
301	Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. <i>Journal of Clinical Oncology</i> , 2016 , 34, 144-50	2.2	76
300	Non-randomized phase II study to assess the efficacy of pembrolizumab (Pem) plus radiotherapy (RT) or ablation in mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC) patients.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3539-3539	2.2	32
299	PKLR promotes colorectal cancer liver colonization through induction of glutathione synthesis. <i>Journal of Clinical Investigation</i> , 2016 , 126, 681-94	15.9	37
298	Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2141-7	2.2	170
297	Faster FOLFOX: Oxaliplatin Can Be Safely Infused at a Rate of 1 mg/m2/min. <i>Journal of Oncology Practice</i> , 2016 , 12, e548-53	3.1	2

296	Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database. <i>Journal of Geriatric Oncology</i> , 2016 , 7, 422-429	3.6	6
295	Extracellular metabolic energetics can promote cancer progression. <i>Cell</i> , 2015 , 160, 393-406	56.2	217
294	Primary tumor location as a prognostic factor in metastatic colorectal cancer. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	298
293	American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2563-77	2.2	599
292	The Cost and Value of Anti-Epidermal Growth Factor Receptor Therapies: Let's Not Be Rash. <i>JAMA Oncology</i> , 2015 , 1, 141-2	13.4	4
291	Genomic Profiling of Cancers of Unknown Primary Site: The Next Steps. <i>JAMA Oncology</i> , 2015 , 1, 541-2	13.4	0
290	Axillary Lymph Node Involvement, a Unique Pattern of Metastasis in BRAF-Mutant Colorectal Cancer. <i>JAMA Oncology</i> , 2015 , 1, 686-7	13.4	5
289	Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population. <i>Annals of Oncology</i> , 2015 , 26, 950-958	10.3	8
288	Translational Considerations on the Outlook of Immunotherapy for Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2015 , 11, 92-97	1	4
287	Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4032-8	2.2	424
286	Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). <i>Journal of Clinical Oncology</i> , 2015 , 33, 3598-607	2.2	44
285	Phase 1 study of APTO-253 HCl, an inducer of KLF4, in patients with advanced or metastatic solid tumors. <i>Investigational New Drugs</i> , 2015 , 33, 1086-92	4.3	22
284	Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. <i>Journal of the National Cancer Institute</i> , 2015 , 107, 345	9.7	101
283	Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. <i>Journal of Clinical Oncology</i> , 2015 , 33, 22-8	2.2	69
282	Rectal Cancer, Version 2.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 719-28; quiz 728	7.3	154
281	Neuroendocrine tumors, version 1.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 78-108	7.3	241
280	Identification of germline genetic mutations in patients with pancreatic cancer. <i>Cancer</i> , 2015 , 121, 4382-8	8.4	117
279	Lymph Node Metastasis Predicts Disease Recurrence in a Single-Center Experience of 70 Stages 1-3 Appendix Cancers: A Retrospective Review. <i>Annals of Surgical Oncology</i> , 2015 , 22, 3613-7	3.1	17

278	Reply to A. Messori et al, R. Bordonaro et al, and G. Fasola et al. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3843-4	2.2	
277	RAF plus EGFR Inhibition for BRAF-Mutant Metastatic Colorectal Cancer-Response. <i>Clinical Cancer Research</i> , 2015 , 21, 2188	12.9	1
276	Serum 25-hydroxy vitamin D and survival in advanced colorectal cancer: a retrospective analysis. <i>Nutrition and Cancer</i> , 2015 , 67, 424-30	2.8	32
275	Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. <i>Clinical Cancer Research</i> , 2015 , 21, 1313-20	12.9	189
274	Hospitalists on an inpatient tertiary care oncology teaching service. <i>Journal of Oncology Practice</i> , 2015 , 11, e114-9	3.1	6
273	Liver-directed conversion therapy in metastatic colon cancer. <i>Journal of Gastrointestinal Oncology</i> , 2015 , 6, 322-8	2.8	1
272	Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. <i>Journal of Clinical Oncology</i> , 2014 , 32, 513-8	2.2	303
271	Comparison of tumor regression grade systems for locally advanced rectal cancer after multimodality treatment. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	120
270	Ganetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancer. <i>Clinical Colorectal Cancer</i> , 2014 , 13, 207-12	3.8	29
269	BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. <i>Cancer</i> , 2014 , 120, 2316-24	6.4	136
268	CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. <i>Gastroenterology</i> , 2014 , 147, 637-45	13.3	95
267	False-positive elevations of carcinoembryonic antigen in patients with a history of resected colorectal cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014 , 12, 907-13	7.3	61
266	Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014 , 12, 513-9	7.3	136
265	Occult primary, version 3.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014 , 12, 969-74	7.3	18
264	Colon cancer, version 3.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014 , 12, 1028-59	7.3	171
263	Sugar-sweetened beverage intake and cancer recurrence and survival in CALGB 89803 (Alliance). <i>PLoS ONE</i> , 2014 , 9, e99816	3.7	46
262	MRE11-deficiency associated with improved long-term disease free survival and overall survival in a subset of stage III colon cancer patients in randomized CALGB 89803 trial. <i>PLoS ONE</i> , 2014 , 9, e108483	3.7	12
261	Pharmacogenomic modeling of circulating tumor and invasive cells for prediction of chemotherapy response and resistance in pancreatic cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 5281-9	12.9	42

260	Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. <i>Genome Biology</i> , 2014 , 15, 454	18.3	224
259	Biologic agents in the treatment of colorectal cancer: an update. <i>Colorectal Cancer</i> , 2014 , 3, 363-374	0.8	1
258	Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2975-84	2.2	77
257	Colorectal cancer survivors Needs and preferences for survivorship information. <i>Journal of Oncology Practice</i> , 2014 , 10, e277-82	3.1	22
256	ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	48
255	Neuroendocrine Tumors 2014 , 595-600		
254	A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2014 , 60, 319-24	13.4	72
253	Hospital-based health care use correlates with incidence of adverse events among elderly Medicare patients treated in adjuvant chemotherapy trials (Alliance 70802). <i>Journal of Geriatric Oncology</i> , 2014 , 5, 230-7	3.6	3
252	A 39-year-old female patient with metastatic rectal cancer develops thrombocytopenia. <i>Gastrointestinal Cancer Research: GCR</i> , 2014 , 7, 55-8		0
251	30-day-or-sooner readmissions of gastrointestinal medical oncology patients following cancer center inpatient service discharge: characteristics and preventability 2014 , 42, 34-44		7
250	Use of Chemotherapy in the Resection of Liver Metastases of Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2013 , 9, 178-184	1	
249	A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas. <i>British Journal of Cancer</i> , 2013 , 109, 915-9	8.7	90
248	Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance. <i>Clinical Colorectal Cancer</i> , 2013 , 12, 233-8	3.8	24
247	Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 1789-98	9.7	39
246	Incidence of chemotherapy-induced amenorrhea in premenopausal women treated with adjuvant FOLFOX for colorectal cancer. <i>Clinical Colorectal Cancer</i> , 2013 , 12, 163-7	3.8	23
245	Intensity-modulated radiotherapy vs. conventional radiotherapy in the treatment of anal squamous cell carcinoma: a propensity score analysis. <i>Radiotherapy and Oncology</i> , 2013 , 107, 189-94	5.3	34
244	Comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients: findings from CALGB 89803 and CALGB 80405. <i>Clinical Colorectal Cancer</i> , 2013 , 12, 95-102	3.8	13
243	Goblet cell carcinoid neoplasm of the appendix: clinical and CT features. <i>European Journal of Radiology</i> , 2013 , 82, 85-9	4.7	18

242	Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2600-6	2.2	171
241	Serial measurement of hepatic lipids during chemotherapy in patients with colorectal cancer: a 1 H MRS study. <i>NMR in Biomedicine</i> , 2013 , 26, 204-12	4.4	5
240	Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803. <i>Clinical Cancer Research</i> , 2013 , 19, 5777-87	12.9	31
239	Neither FDG-PET Nor CT can distinguish between a pathological complete response and an incomplete response after neoadjuvant chemoradiation in locally advanced rectal cancer: a prospective study. <i>Annals of Surgery</i> , 2013 , 258, 289-95	7.8	78
238	TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial. <i>Cancer</i> , 2013 , 119, 4290-8	6.4	47
237	Frequency, characteristics, and correlates of pain in a pilot study of colorectal cancer survivors 1-10 years post-treatment. <i>Pain Medicine</i> , 2013 , 14, 1673-80	2.8	14
236	Role of expression profiling in carcinoma of unknown primary remains unknown. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2513-4	2.2	8
235	Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013 , 11, 141-52; quiz 152	7.3	118
234	Systemic therapy for metastatic colorectal cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013 , 11, 649-52	7.3	9
233	Localized colon cancer, version 3.2013: featured updates to the NCCN Guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013 , 11, 519-28	7.3	77
232	Study using the NCCN guidelines for palliative care to screen patients for palliative care needs and referral to palliative care specialists. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013 , 11, 1087-96	7.3	27
231	Management of a patient diagnosed with pancreatic cancer and myelodysplastic syndrome. <i>Gastrointestinal Cancer Research: GCR</i> , 2013 , 6, 56-60		2
230	A 40-year-old woman with locally advanced rectal cancer and a solitary liver metastasis. <i>Gastrointestinal Cancer Research: GCR</i> , 2013 , 6, 87-9		1
229	Modified GTX as Second-Line Chemotherapy in Advanced Pancreatic Cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2013 , 6, 115-7		
228	Adenocarcinoma of the Colon and Rectum 2013 , 2051-2074		
227	Biologic Agents in the Treatment of Colorectal Cancer: The Last Decade; the Lost Decade?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013 , e121-e125	7.1	
226	Colorectal cancer patients with oligometastatic liver disease: what is the optimal approach?. <i>Oncology</i> , 2013 , 27, 1074-8	1.8	24
225	Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer. <i>Clinical Colorectal Cancer</i> , 2012 , 11, 101-11	3.8	58

224	Pathologic response to preoperative chemotherapy in colorectal liver metastases: fibrosis, not necrosis, predicts outcome. <i>Annals of Surgical Oncology</i> , 2012 , 19, 2797-804	3.1	46
223	Unusual DNA mismatch repair-deficient tumors in Lynch syndrome: a report of new cases and review of the literature. <i>Human Pathology</i> , 2012 , 43, 1677-87	3.7	79
222	Treatment Options for Patients With Unresectable Colorectal Cancer With Wild-Type KRAS. <i>Current Colorectal Cancer Reports</i> , 2012 , 8, 170-176	1	
221	A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors. <i>Cancer</i> , 2012 , 118, 4795-800	6.4	50
220	Patterns of failure in patients with early onset (synchronous) resectable liver metastases from rectal cancer. <i>Cancer</i> , 2012 , 118, 5414-23	6.4	29
219	Dynamic contrast enhanced-MRI for the detection of pathological complete response to neoadjuvant chemotherapy for locally advanced rectal cancer. <i>European Radiology</i> , 2012 , 22, 821-31	8	113
218	Comparative genomic analysis of primary versus metastatic colorectal carcinomas. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2956-62	2.2	225
217	Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. <i>Journal of the National Cancer Institute</i> , 2012 , 104, 1702-11	9.7	114
216	Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. <i>Clinical Cancer Research</i> , 2012 , 18, 890-900	12.9	219
215	Anal Carcinoma, Version 2.2012: featured updates to the NCCN guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012 , 10, 449-54	7.3	56
214	FDG-PET assessment of rectal cancer response to neoadjuvant chemoradiotherapy is not associated with long-term prognosis: a prospective evaluation. <i>Diseases of the Colon and Rectum</i> , 2012 , 55, 378-86	3.1	20
213	Pulmonary recurrence predominates after combined modality therapy for rectal cancer: an original retrospective study. <i>Annals of Surgery</i> , 2012 , 256, 111-6	7.8	56
212	Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy. <i>Annals of Surgery</i> , 2012 , 256, 965-72	7.8	259
211	Neuroendocrine tumors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012 , 10, 724-64.3	4.3	135
210	BRAF mutations in colorectal cancer: clinical relevance and role in targeted therapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012 , 10, 1456-8	7.3	8
209	Unusual Tumors of the Colon, Rectum, And Anus 2012 , 453-463		
208	Rectal cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012 , 10, 1528-64	7.3	127
207	Curative-Intent Treatment for Colorectal Liver Metastases: A Medical Oncologist's Perspective. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012 , 205-8	7.1	1

206	Neoadjuvant Therapy in Clinical Stage II Pancreatic Adenocarcinoma. <i>Gastrointestinal Cancer Research: GCR</i> , 2012 , 5, 169-73		
205	Advances in systemic therapy for hepatocellular carcinoma 2012 , 1444-1452.e3		
204	Doxorubicin and sorafenib for treatment of advanced hepatocellular cancer. <i>Gastroenterology</i> , 2011 , 141, e19-20; author reply e20-1	13.3	6
203	Surgery and high-dose-rate intraoperative radiation therapy for recurrent squamous-cell carcinoma of the anal canal. <i>Diseases of the Colon and Rectum</i> , 2011 , 54, 1090-7	3.1	22
202	NCCN Clinical Practice Guidelines Occult primary. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011 , 9, 1358-95	7.3	25
201	Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3153-62	2.2	134
200	Evaluation of ¹⁸ F-FDG-PET for early detection of suboptimal response of rectal cancer to preoperative chemoradiotherapy: a prospective analysis. <i>Annals of Surgical Oncology</i> , 2011 , 18, 2783-9	3.1	32
199	Recurrence rates and prognostic factors in ypN0 rectal cancer after neoadjuvant chemoradiation and total mesorectal excision. <i>Annals of Surgical Oncology</i> , 2011 , 18, 3666-72	3.1	31
198	BEYOND KRAS: Other markers and potential treatment strategies for KRAS mutant and wild-type patients. <i>Current Treatment Options in Oncology</i> , 2011 , 12, 126-35	5.4	2
197	Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1757-64	2.2	163
196	XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. <i>British Journal of Cancer</i> , 2011 , 105, 58-64	8.7	160
195	Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. <i>Journal of Clinical Oncology</i> , 2011 , 29, 83-8	2.2	135
194	Addition of octreotide functional imaging to cross-sectional computed tomography or magnetic resonance imaging for the detection of neuroendocrine tumors: added value or an anachronism?. <i>Journal of Clinical Oncology</i> , 2011 , 29, e74-5	2.2	23
193	Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 1498-506	9.7	47
192	Palliative care in the outpatient oncology setting: evaluation of a practical set of referral criteria. <i>Journal of Oncology Practice</i> , 2011 , 7, 366-70	3.1	51
191	KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice. <i>Oncologist</i> , 2011 , 16, 1061-8	5.7	14
190	Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients. <i>Annals of Oncology</i> , 2011 , 22, 2604-2609	10.3	64
189	Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 1540-51	9.7	58

188	Phase I study of two schedules of oral S-1 in combination with fixed doses of oxaliplatin and bevacizumab in patients with advanced solid tumors. <i>Oncology</i> , 2011 , 81, 65-72	3.6	5
187	Colon cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011 , 9, 1238-90	7.3	39
186	Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4240-6	2.2	115
185	Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3485-90	2.2	216
184	Advanced hepatocellular carcinoma: which staging systems best predict prognosis?. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2889-95	2.2	242
183	Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2010 , 304, 2154-60	27.4	344
182	Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer: findings from CALGB 89803. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4354-63	2.2	28
181	Adjuvant therapy for colon cancer. <i>Surgical Oncology Clinics of North America</i> , 2010 , 19, 819-27	2.7	23
180	Genomic and biological characterization of exon 4 KRAS mutations in human cancer. <i>Cancer Research</i> , 2010 , 70, 5901-11	10.1	218
179	NCCN clinical practice guidelines in oncology. Anal carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010 , 8, 106-20	7.3	53
178	ACR Appropriateness Criteria: local excision in early-stage rectal cancer. <i>Current Problems in Cancer</i> , 2010 , 34, 193-200	2.3	10
177	Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010 , 136, 737-43	4.9	131
176	Evaluation of Bevacizumab in the Adjuvant Treatment of Colon Cancer. <i>Current Colorectal Cancer Reports</i> , 2010 , 6, 109-110	1	
175	Evolving treatment of advanced colorectal cancer. <i>Current Oncology Reports</i> , 2010 , 12, 153-9	6.3	14
174	Impact of smoking on patients with stage III colon cancer: results from Cancer and Leukemia Group B 89803. <i>Cancer</i> , 2010 , 116, 957-66	6.4	51
173	ACR Appropriateness Criteria: rectal cancer-metastatic disease at presentation. <i>Current Problems in Cancer</i> , 2010 , 34, 201-10	2.3	9
172	Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010 , 78, 1064-72	4	58
171	Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study). <i>Anticancer Research</i> , 2010 , 30, 4209-17	2.3	27

170	Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1948-55	2.2	125
169	p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803. <i>Clinical Cancer Research</i> , 2009 , 15, 2116-22	12.9	14
168	Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1814-21	2.2	301
167	Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors. <i>Nature Reviews Clinical Oncology</i> , 2009 , 6, 143-52	19.4	20
166	KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. <i>Clinical Cancer Research</i> , 2009 , 15, 7322-9	12.9	159
165	Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer. <i>Investigational New Drugs</i> , 2009 , 27, 366-73	4.3	4
164	Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. <i>British Journal of Cancer</i> , 2009 , 101, 1033-8	8.7	138
163	A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption. <i>Journal of the American Academy of Dermatology</i> , 2009 , 61, 614-20	4.5	52
162	Prognostic factors for recurrence after pulmonary resection of colorectal cancer metastases. <i>Annals of Thoracic Surgery</i> , 2009 , 87, 1684-8	2.7	140
161	Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3379-84	2.2	308
160	Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors. <i>Cancer Investigation</i> , 2009 , 27, 402-6	2.1	1
159	Evolving treatment of advanced colon cancer. <i>Annual Review of Medicine</i> , 2009 , 60, 207-19	17.4	111
158	NCCN Clinical Practice Guidelines in Oncology: rectal cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009 , 7, 838-81	7.3	240
157	NCCN Clinical Practice Guidelines in Oncology: colon cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009 , 7, 778-831	7.3	325
156	NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009 , 7 Suppl 1, S5-21; quiz S22-4	7.3	87
155	Looking ahead: what will change in colorectal cancer treatment?. <i>Gastrointestinal Cancer Research: GCR</i> , 2009 , 3, S16-8		3
154	Current role of bevacizumab in colorectal cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2009 , 7, 375-6	0.6	1
153	First-line treatment of patients with metastatic colorectal cancer: an overview of recent data on chemotherapy plus targeted agents. <i>Clinical Colorectal Cancer</i> , 2008 , 7 Suppl 2, S47-51	3.8	5

152	Systemic therapy for colon cancer. <i>Gastroenterology Clinics of North America</i> , 2008 , 37, 287-95, ix	4.4	17
151	Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2013-9 ^{2.2}	23	28
150	Individualized prediction of colon cancer recurrence using a nomogram. <i>Journal of Clinical Oncology</i> , 2008 , 26, 380-5	2.2	202
149	Potential regional differences for the tolerability profiles of fluoropyrimidines. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2118-23	2.2	194
148	Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1443-51	2.2	181
147	Association of family history with cancer recurrence and survival among patients with stage III colon cancer. <i>JAMA - Journal of the American Medical Association</i> , 2008 , 299, 2515-23	27.4	56
146	Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4109-15	2.2	201
145	Progress in cancer care: the hope, the hype, and the gap between reality and perception. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5020-1	2.2	30
144	A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. <i>Annals of Oncology</i> , 2008 , 19, 86-91	10.3	60
143	Is adjuvant therapy for stage II colon cancer worthwhile, and for whom?. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2008 , 5, 422-3		5
142	Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2006-12	2.2	667
141	Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity?. <i>American Journal of Surgical Pathology</i> , 2008 , 32, 719-31	6.7	145
140	The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor. <i>Investigational New Drugs</i> , 2008 , 26, 45-51	4.3	192
139	Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. <i>Cancer</i> , 2008 , 113, 57-64	6.4	189
138	ACR Appropriateness Criteria on resectable rectal cancer: expert panel on radiation oncology--rectal/anal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008 , 70, 1427-30	4	7
137	Current management of advanced hepatocellular carcinoma. <i>Gastrointestinal Cancer Research: GCR</i> , 2008 , 2, 64-70		18
136	Second- and third-line treatment options for unresectable metastatic colorectal cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2008 , 2, 299-302		1
135	Combination chemotherapy: the fallback position?. <i>Gastrointestinal Cancer Research: GCR</i> , 2008 , 2, 154-5		

134	Colorectal Cancer Treatment: What's Next? (or: Is There Life After EGFR and VEGF?). <i>Gastrointestinal Cancer Research: GCR</i> , 2008 , 2, S20-2		9
133	Occult primary. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2008 , 6, 1026-60	7.3	2
132	ACR Appropriateness Criteria on treatment of anal cancer. <i>Journal of the American College of Radiology</i> , 2007 , 4, 448-56	3.5	12
131	Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study. <i>Annals of Surgical Oncology</i> , 2007 , 14, 759-65	3.1	135
130	Targeted therapy for metastatic colorectal cancer: Current challenges and future directions. <i>Current Colorectal Cancer Reports</i> , 2007 , 3, 109-115	1	1
129	Bevacizumab 5 mg/kg can be infused safely over 10 minutes. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2691-5	12.5	43
128	Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4557-61	2.2	349
127	End points in advanced colon cancer clinical trials: a review and proposal. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3572-5	2.2	61
126	Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. <i>Journal of Clinical Oncology</i> , 2007 , 25, 5390-6	2.2	223
125	Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. <i>JAMA - Journal of the American Medical Association</i> , 2007 , 298, 754-64	27.4	294
124	Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4793-9	2.2	131
123	Targeted strategies in the treatment of metastatic colon cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007 , 5, 983-90	7.3	6
122	Adjuvant therapy of colon cancer: current status and future directions. <i>Cancer Journal (Sudbury, Mass)</i> , 2007 , 13, 192-7	2.2	48
121	Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3456-61	2.2	351
120	Oxaliplatin and irinotecan: From advanced to adjuvant therapy of colon cancer. <i>Current Colorectal Cancer Reports</i> , 2006 , 2, 142-148	1	
119	Planned treatment interruptions and chemotherapy-free intervals in the treatment of metastatic colorectal cancer: time to start stopping?. <i>Seminars in Oncology</i> , 2006 , 33, S28-32	5.5	5
118	Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas, and normal mucosa. <i>Cancer</i> , 2006 , 106, 1857-62	6.4	31
117	Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3535-41	2.2	567

116	Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 4293-300	2.2	1002
115	Ten-year results of preoperative radiation followed by sphincter preservation for rectal cancer: increased local failure rate in nonresponders. <i>Clinical Colorectal Cancer</i> , 2006 , 5, 413-21	3.8	14
114	Unusual Tumors of the Colon, Rectum and Anus 2006 , 401-409		
113	Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer?. <i>Nature Clinical Practice Oncology</i> , 2005 , 2, 20-1		7
112	Cetuximab therapy and symptomatic hypomagnesemia. <i>Journal of the National Cancer Institute</i> , 2005 , 97, 1221-4	9.7	195
111	Epidermal growth factor receptor-negative colorectal cancer: is there truly such an entity?. <i>Clinical Colorectal Cancer</i> , 2005 , 5 Suppl 2, S98-100	3.8	36
110	Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. <i>Annals of Surgery</i> , 2005 , 241, 829-36; discussion 836-8	7.8	301
109	Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005 , 62, 1363-70	4	68
108	Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. <i>Modern Pathology</i> , 2005 , 18, 1350-6	9.8	125
107	Complications after preoperative combined modality therapy and radical resection of locally advanced rectal cancer: a 14-year experience from a specialty service. <i>Journal of the American College of Surgeons</i> , 2005 , 200, 876-82; discussion 882-4	4.4	66
106	Developing a cancer-specific geriatric assessment: a feasibility study. <i>Cancer</i> , 2005 , 104, 1998-2005	6.4	435
105	Metabolic signatures associated with a NAD synthesis inhibitor-induced tumor apoptosis identified by 1H-decoupled-31P magnetic resonance spectroscopy. <i>Clinical Cancer Research</i> , 2005 , 11, 3503-13	12.9	84
104	A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. <i>Clinical Cancer Research</i> , 2005 , 11, 3836-45	12.9	99
103	Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 2005 , 23, 1875-84	2.2	102
102	HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. <i>Oncologist</i> , 2005 , 10, 345-56	5.7	232
101	Distal cT2N0 rectal cancer: is there an alternative to abdominoperineal resection?. <i>Journal of Clinical Oncology</i> , 2005 , 23, 4905-12	2.2	39
100	Antibody-based therapies for colorectal cancer. <i>Oncologist</i> , 2005 , 10, 701-9	5.7	41
99	Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?. <i>Journal of Clinical Oncology</i> , 2005 , 23, 5235-46	2.2	430

98	Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. <i>Journal of Clinical Oncology</i> , 2005 , 23, 9073-8	2.2	121
97	Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. <i>Journal of Clinical Oncology</i> , 2005 , 23, 1803-10	2.2	943
96	ACCO: ASCO core curriculum outline. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2049-77	2.2	29
95	Clinical examination following preoperative chemoradiation for rectal cancer is not a reliable surrogate end point. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3475-9	2.2	132
94	Metastatic colorectal cancer: is there one standard approach?. <i>Oncology</i> , 2005 , 19, 1147-54; discussion 1154, 1157-8, 1160	1.8	16
93	Use of surgery among elderly patients with stage IV colorectal cancer. <i>Journal of Clinical Oncology</i> , 2004 , 22, 3475-84	2.2	184
92	Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer. <i>Journal of the American College of Surgeons</i> , 2004 , 199, 1-7	4.4	149
91	Expression of p27 in residual rectal cancer after preoperative chemoradiation predicts long-term outcome. <i>Annals of Surgical Oncology</i> , 2004 , 11, 955-61	3.1	21
90	A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for five days every three weeks to patients with metastatic adenocarcinoma of the colon or rectum. <i>Investigational New Drugs</i> , 2004 , 22, 53-61	4.3	10
89	Neuroendocrine carcinomas of the colon and rectum. <i>Diseases of the Colon and Rectum</i> , 2004 , 47, 163-9	3.1	241
88	Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection. <i>Diseases of the Colon and Rectum</i> , 2004 , 47, 279-86	3.1	205
87	Oncologic outcomes of salvage surgery for epidermoid carcinoma of the anus initially managed with combined modality therapy. <i>Diseases of the Colon and Rectum</i> , 2004 , 47, 1136-44	3.1	97
86	Palliative management of rectal cancer: the roles of chemotherapy and radiation therapy. <i>Journal of Gastrointestinal Surgery</i> , 2004 , 8, 274-6	3.3	10
85	Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. <i>Journal of Clinical Oncology</i> , 2004 , 22, 1201-8	2.2	1492
84	Phase I trial of sequential raltitrexed followed by bolus 5-fluorouracil in patients with advanced colorectal cancer. <i>Anti-Cancer Drugs</i> , 2004 , 15, 219-27	2.4	7
83	Irinotecan (Campto) in the treatment of pancreatic cancer. <i>Expert Review of Anticancer Therapy</i> , 2003 , 3, 587-93	3.5	13
82	Adequacy of 1-cm distal margin after restorative rectal cancer resection with sharp mesorectal excision and preoperative combined-modality therapy. <i>Annals of Surgical Oncology</i> , 2003 , 10, 80-5	3.1	177
81	Primary adenocarcinoma of the anus treated with combined modality therapy. <i>Diseases of the Colon and Rectum</i> , 2003 , 46, 1320-4	3.1	40

80	The camptothecins. <i>Lancet, The</i> , 2003 , 361, 2235-42	40	336
79	Another study of how to give fluorouracil?. <i>Journal of Clinical Oncology</i> , 2003 , 21, 3711-2	2.2	7
78	Colon cancer. Clinical practice guidelines in oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2003 , 1, 40-53	7.3	28
77	Anal canal cancer. Clinical practice guidelines in oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2003 , 1, 64-8	7.3	6
76	Understanding and managing chemotherapy-induced diarrhea. <i>The Journal of Supportive Oncology</i> , 2003 , 1, 35-46; discussion 38-41, 45-6		24
75	Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients. <i>Journal of the American College of Surgeons</i> , 2002 , 194, 131-5; discussion 135-6	4.4	291
74	Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease. <i>Annals of Surgical Oncology</i> , 2002 , 9, 954-60	3.1	62
73	Safe and cost effective use of alteplase for the clearance of occluded central venous access devices. <i>Journal of Clinical Oncology</i> , 2002 , 20, 1918-22	2.2	25
72	Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. <i>Journal of Clinical Oncology</i> , 2002 , 20, 3999-4005	2.2	192
71	A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan. <i>Annals of Oncology</i> , 2002 , 13, 1067-71	10.3	72
70	Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related tumors. <i>Journal of Clinical Oncology</i> , 2002 , 20, 4673-8	2.2	224
69	Irinotecan in the Treatment of Colorectal Cancer 2002 , 513-524		
68	Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer. <i>Annals of Oncology</i> , 2002 , 13, 1490-6	10.3	14
67	Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 2002 , 20, 2157-70	2.2	144
66	Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. <i>Annals of Surgery</i> , 2002 , 236, 75-81	7.8	214
65	Adjuvant therapy of cancers of the colon and rectum. <i>Surgical Clinics of North America</i> , 2002 , 82, 1035-58	40	
64	Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease 2002 , 9, 954		2
63	Adjuvant Therapy for Colon Cancer 2002 , 585-596		

62	Surgical debulking and intraperitoneal chemotherapy for established peritoneal metastases from colon and appendix cancer. <i>Annals of Surgical Oncology</i> , 2001 , 8, 787-95	3.1	111
61	Abdominoperineal resection for rectal cancer at a specialty center. <i>Diseases of the Colon and Rectum</i> , 2001 , 44, 27-35; discussion 35-6	3.1	97
60	Preoperative combined modality therapy for clinically resectable uT3 rectal adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001 , 49, 987-95	4	136
59	A phase II study of irinotecan in patients with advanced hepatocellular carcinoma. <i>Cancer</i> , 2001 , 91, 101-5.	6.4	70
58	Irinotecan: a new agent comes of age. <i>Oncologist</i> , 2001 , 6, 65	5.7	4
57	Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. <i>Oncologist</i> , 2001 , 6, 81-91	5.7	110
56	Recommendation for irinotecan, 5-fluorouracil, and leucovorin as first-line therapy for colorectal cancer. <i>Clinical Colorectal Cancer</i> , 2001 , 1, 82-4	3.8	
55	New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer. <i>Lancet Oncology, The</i> , 2001 , 2, 290-7	21.7	30
54	Capecitabine monotherapy in metastatic colorectal cancer [Authors'Reply. <i>Lancet Oncology, The</i> , 2001 , 2, 400	21.7	
53	Islet cell tumors of the pancreas: the medical oncologist's perspective. <i>Surgical Clinics of North America</i> , 2001 , 81, 527-42	4	107
52	Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. <i>Journal of Clinical Oncology</i> , 2001 , 19, 1985-92	2.2	177
51	A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma. <i>Annals of Oncology</i> , 2001 , 12, 501-4	10.3	33
50	Surgical Debulking and Intraperitoneal Chemotherapy for Established Peritoneal Metastases From Colon and Appendix Cancer 2001 , 8, 787		6
49	Author reply. <i>Cancer</i> , 2000 , 88, 2195	6.4	
48	High-dose-rate intraoperative brachytherapy for recurrent colorectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000 , 48, 219-26	4	100
47	Hepatic neuroendocrine metastases: does intervention alter outcomes?. <i>Journal of the American College of Surgeons</i> , 2000 , 190, 432-45	4.4	539
46	Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography. <i>Diseases of the Colon and Rectum</i> , 2000 , 43, 18-24	3.1	131
45	Oral chemotherapeutic agents for colorectal cancer. <i>Oncologist</i> , 2000 , 5, 99-107	5.7	30

44	Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. <i>New England Journal of Medicine</i> , 2000 , 343, 905-14	59.2	2534
43	Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. <i>Journal of Clinical Oncology</i> , 1999 , 17, 600-6	2.2	317
42	Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. <i>Journal of Clinical Oncology</i> , 1999 , 17, 3270-5	2.2	215
41	A phase II trial of interferon alpha-2a and carboplatin in patients with advanced malignant mesothelioma. <i>Cancer Investigation</i> , 1999 , 17, 195-200	2.1	27
40	Conservative management of rectal cancer with local excision and postoperative adjuvant therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999 , 44, 841-846	4	63
39	The role of irinotecan in colorectal cancer. <i>Current Oncology Reports</i> , 1999 , 1, 155-60	6.3	6
38	Phase II clinical trial of 13-cis-retinoic acid and interferon-alpha-2a in patients with advanced esophageal carcinoma. <i>Cancer</i> , 1999 , 85, 1213-7	6.4	12
37	Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma 1999 , 86, 944-948		144
36	Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma 1999 , 86, 944		2
35	Adjuvant therapy for colorectal cancer. <i>Current Problems in Cancer</i> , 1998 , 22, 11-77	2.3	24
34	Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 1998 , 16, 3858-65	2.2	38
33	Adjuvant treatment of colorectal cancer. <i>Annual Review of Medicine</i> , 1997 , 48, 191-202	17.4	18
32	Adjuvant therapy for colorectal cancer. <i>Current Problems in Surgery</i> , 1997 , 34, 601-76	2.8	38
31	Adjuvant Therapy of Colorectal Cancer. <i>Surgical Oncology Clinics of North America</i> , 1997 , 6, 699-722	2.7	8
30	Preliminary results of preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for clinically resectable T3 rectal cancer. <i>Diseases of the Colon and Rectum</i> , 1997 , 40, 515-22	3.1	190
29	Preoperative 5-FU, low-dose leucovorin, and radiation therapy for locally advanced and unresectable rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997 , 37, 289-95	4	153
28	9-Aminocamptothecin by 72-hour continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma. <i>Cancer</i> , 1997 , 80, 1727-32	6.4	27
27	Clinical Use of Irinotecan:Current Status and Future Considerations. <i>Oncologist</i> , 1997 , 2, 402-409	5.7	9

26	A phase II study of topotecan administered five times daily in patients with advanced gastric cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1997 , 20, 621-5	2.7	12
25	Clinical Use of Camptosar (CPT-11). <i>Oncologist</i> , 1997 , 2, 191-191	5.7	
24	Clinical Use of Irinotecan: Current Status and Future Considerations. <i>Oncologist</i> , 1997 , 2, 402-409	5.7	4
23	Adjuvant Chemotherapy of Colorectal Cancer. <i>Oncologist</i> , 1996 , 1, 22-29	5.7	8
22	Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 1996 , 14, 2959-67	2.2	123
21	A phase I trial of a modified, dose intensive FAMTX regimen (High dose 5-fluorouracil + doxorubicin + high dose methotrexate + leucovorin) with oral uridine rescue 1996 , 78, 1988-1995		7
20	Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer. <i>Cancer</i> , 1995 , 75, 769-74	6.4	19
19	A fixed-ratio combination of uracil and Ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancer. <i>Cancer</i> , 1995 , 75, 782-5	6.4	91
18	A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma. <i>Cancer</i> , 1995 , 75, 2197-202	6.4	27
17	Peripheral Neuroectodermal Tumor-Ewing® Sarcoma of the Thumb With Local Recurrences and Pleural Metastases After 17 Years: A Unique Clinical Presentation and a Challenging Differential Diagnosis of the So-called Small, Round Cell Neoplasms. <i>International Journal of Surgical Pathology</i> , 1994 , 2, 147-156	1.2	
16	Phase II trial of gemcitabine in patients with advanced gastric cancer. <i>Cancer</i> , 1994 , 73, 5-7	6.4	25
15	Preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for rectal cancer. <i>Cancer</i> , 1994 , 73, 273-80	6.4	113
14	A phase II trial of alpha-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors. <i>Cancer</i> , 1994 , 74, 958-61	6.4	56
13	A phase I trial of immediate postoperative intraperitoneal floxuridine and leucovorin plus systemic 5-fluorouracil and levamisole after resection of high risk colon cancer. <i>Cancer</i> , 1994 , 74, 2224-33	6.4	38
12	A phase I trial of intrahepatic verapamil and doxorubicin. Regional therapy to overcome multidrug resistance. <i>Cancer</i> , 1994 , 74, 2757-64	6.4	12
11	The efficacy of preoperative 5-fluorouracil, high-dose leucovorin, and sequential radiation therapy for unresectable rectal cancer. <i>Cancer</i> , 1993 , 71, 3486-92	6.4	90
10	Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. <i>Cancer</i> , 1993 , 72, 244-8	6.4	242
9	A phase II trial of carboplatin in patients with advanced APUD tumors. <i>Cancer</i> , 1993 , 72, 619-22	6.4	23

8	Pre-operative combined 5-FU, low dose leucovorin, and sequential radiation therapy for unresectable rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 1993 , 25, 821-7	4	51
7	Phase I trial of postoperative 5-FU, radiation therapy, and high dose leucovorin for resectable rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 1992 , 22, 139-45	4	18
6	Preoperative high-dose leucovorin/5-fluorouracil and radiation therapy for unresectable rectal cancer. <i>Cancer</i> , 1991 , 67, 2859-66	6.4	83
5	Drug treatment of colorectal cancer. Current status. <i>Drugs</i> , 1991 , 42, 616-27	12.1	5
4	A phase I trial of cisplatin in hypertonic saline and escalating doses of 5-fluorouracil by continuous intravenous infusion in patients with advanced malignancies. <i>Cancer</i> , 1990 , 66, 1688-91	6.4	5
3	A rectal cancer model establishes a platform to study individual responses to chemoradiation		2
2	PCK1 and DHODH drive colorectal cancer liver metastatic colonization and nucleotide biosynthesis under hypoxia		1
1	PD-1 Blockade in Mismatch Repair Deficient, Locally Advanced Rectal Cancer. <i>New England Journal of Medicine</i> ,	59.2	35